US Stock MarketDetailed Quotes
PMVP PMV Pharmaceuticals
- 1.500
- -0.030-1.96%
Close Sep 6 16:00 ET
77.28MMarket Cap-1562P/E (TTM)
1.560High1.490Low110.16KVolume1.530Open1.530Pre Close166.86KTurnover0.29%Turnover RatioLossP/E (Static)51.52MShares6.98052wk High0.36P/B57.41MFloat Cap1.17552wk Low--Dividend TTM38.27MShs Float63.220Historical High--Div YieldTTM4.58%Amplitude1.175Historical Low1.514Avg Price1Lot Size
PMV Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 87.61%-1.6M | -7.81%-16.18M | 12.71%-55.66M | 21.14%-12.09M | 6.56%-15.66M | 5.69%-12.9M | 16.59%-15.01M | -36.91%-63.76M | -27.40%-15.32M | -35.18%-16.76M |
| Net income from continuing operations | 93.04%-1.21M | 20.17%-15.27M | 5.94%-68.96M | 18.55%-15.76M | 8.72%-16.64M | -0.73%-17.44M | -3.77%-19.13M | -26.75%-73.32M | -5.37%-19.35M | -21.44%-18.23M |
| Depreciation and amortization | 0.81%372K | 111.70%362K | 299.05%1.26M | 378.67%359K | 383.78%358K | 350.00%369K | 103.57%171K | 2.61%315K | -2.60%75K | -7.50%74K |
| Other non cash items | -4.08%-102K | 6.67%-84K | -252.26%-370K | -210.13%-87K | -231.94%-95K | -1,188.89%-98K | -208.43%-90K | -74.55%243K | -75.91%79K | -77.00%72K |
| Change In working capital | -198.94%-2.05M | -219.78%-2.17M | 1,055.46%5.43M | 72.11%2.31M | 14.73%-764K | 117.68%2.07M | 192.46%1.82M | -113.78%-568K | -67.04%1.34M | -401.68%-896K |
| -Change in prepaid assets | -307.54%-1.35M | -108.02%-169K | 194.20%1.72M | -368.12%-984K | 97.30%-51K | 5.52%650K | 328.14%2.11M | -4,913.16%-1.83M | -79.39%367K | -60.95%-1.89M |
| -Change in payables and accrued expense | -166.15%-938K | -584.30%-2.01M | 267.86%2.87M | 739.32%2.46M | -171.80%-713K | 388.21%1.42M | 83.95%-293K | -141.81%-1.71M | -116.79%-384K | -32.45%993K |
| -Change in other current liabilities | ---- | ---- | -71.81%837K | ---- | ---- | ---- | ---- | --2.97M | ---- | ---- |
| -Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---1K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 87.61%-1.6M | -7.81%-16.18M | 12.71%-55.66M | 21.14%-12.09M | 6.56%-15.66M | 5.69%-12.9M | 16.59%-15.01M | -36.91%-63.76M | -27.40%-15.32M | -35.18%-16.76M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 103.63%2.32M | -47.29%26.17M | -3,594.81%-50.55M | -111.14%-2.59M | -213.98%-33.64M | -318.63%-63.96M | 227.87%49.65M | 99.05%-1.37M | 207.22%23.22M | 4,358.73%29.51M |
| Net PPE purchase and sale | 99.29%-4K | -280.77%-594K | 87.95%-962K | 87.97%-197K | 97.85%-44K | 83.86%-565K | 80.40%-156K | -491.85%-7.98M | -525.19%-1.64M | -309.18%-2.05M |
| Net investment purchase and sale | 103.67%2.33M | -46.27%26.76M | -849.44%-49.58M | -109.62%-2.39M | -206.44%-33.6M | -438.23%-63.4M | 230.96%49.8M | 104.65%6.62M | 217.87%24.86M | 16,539.06%31.56M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 103.63%2.32M | -47.29%26.17M | -3,594.81%-50.55M | -111.14%-2.59M | -213.98%-33.64M | -318.63%-63.96M | 227.87%49.65M | 99.05%-1.37M | 207.22%23.22M | 4,358.73%29.51M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -93.38%141K | 0 | 3,613.67%35.58M | -47.45%288K | 552,333.33%33.15M | 672.10%2.13M | -90.63%12K | -52.62%958K | 85.76%548K | -98.06%6K |
| Net common stock issuance | ---- | ---- | --35.12M | --0 | --33.1M | ---- | ---- | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | 34.29%141K | --0 | -52.40%456K | -47.45%288K | 750.00%51K | -61.96%105K | -90.63%12K | -52.62%958K | 85.76%548K | -98.06%6K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -93.38%141K | --0 | 3,613.67%35.58M | -47.45%288K | 552,333.33%33.15M | 672.10%2.13M | -90.63%12K | -52.62%958K | 85.76%548K | -98.06%6K |
| Net cash flow | ||||||||||
| Beginning cash position | -66.28%48.48M | -64.69%38.53M | -37.03%109.12M | -47.47%52.88M | -21.48%69.03M | 23.30%143.76M | -37.03%109.12M | -52.05%173.29M | -43.27%100.67M | -53.79%87.91M |
| Current changes in cash | 101.16%866K | -71.19%9.98M | -10.06%-70.63M | -270.30%-14.39M | -226.58%-16.15M | -160.56%-74.73M | 161.11%34.65M | 65.89%-64.17M | 302.37%8.45M | 199.83%12.76M |
| Effect of exchange rate changes | --6K | ---34K | --34K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| End cash Position | -28.51%49.35M | -66.28%48.48M | -64.69%38.53M | -64.69%38.53M | -47.47%52.88M | -21.48%69.03M | 23.30%143.76M | -37.03%109.12M | -37.03%109.12M | -43.27%100.67M |
| Free cash flow | 88.10%-1.6M | -10.61%-16.78M | 21.08%-56.62M | 27.59%-12.28M | 16.51%-15.7M | 21.61%-13.47M | 19.29%-15.17M | -49.72%-71.74M | -38.01%-16.96M | -45.82%-18.81M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg